D-0336-2018 Class II Terminated

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0336-2018 was initiated by Glenmark Pharmaceuticals Inc., USA on Nov 20, 2017 and is designated Class II. Reason for recall: CGMP Deviations: Market complaints related to "gritty texture". The recall status is terminated (terminated Oct 3, 2018). Affected quantity: 5136 tubes.

Recall details

Product Type
Drugs
Report Date
Feb 7, 2018
Initiation Date
Nov 20, 2017
Termination Date
Oct 3, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5136 tubes

Product description

Glenmark Mometasone Furoate Cream, USP, 0.1%, 45 g Rx Only Manufactured by: Glenmark Pharmaceuticals Ltd. Village Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 NDC 68462019255 UPC 3684620192559

Reason for recall

CGMP Deviations: Market complaints related to "gritty texture".

Distribution pattern

Product was distributed throughout the United States.

Code information

Batch Number: 05170598; Exp. 03/19

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0336-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0336-2018. Report a data issue: hello@regdatalab.com.